trending Market Intelligence /marketintelligence/en/news-insights/trending/QkEti91rV-zWfs0iRQh4NA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Provention's type 1 diabetes drug gets EMA priority medicines tag

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Provention's type 1 diabetes drug gets EMA priority medicines tag

Provention Bio Inc.'s teplizumab, or PRV-031, was granted the priority-medicines designation by the European Medicines Agency.

SNL Image

Teplizumab is being developed to either prevent or delay type 1 diabetes in people who are at risk of developing the disorder. Most often these people are completely unable to produce insulin, and Provention's medicine is designed to restore the function of certain cells in the pancreas that synthesize insulin and reduces the need for patients to get it from other means.

The PRIME designation, granted by the EMA's Committee for Medicinal Products for Human Use, is designed to expedite the development of medicines that target an unmet medical need and that may offer a major therapeutic advantage over existing treatments.

Previously, teplizumab received the U.S. Food and Drug Administration's breakthrough-therapy designation for the same indication.

The designations are based on a mid-stage study that showed the drug can delay the onset of type 1 diabetes by at least two years, both in adults and children.

Recently the Oldwick, N.J.-based pharmaceutical company secured $62.7 million via a public offering and a private placement primarily to finance U.S. regulatory submission for teplizumab.